Peter Sheldrake
Institute of Cancer Research(GB)Cancer Research UK(GB)
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, Protein Kinase Regulation and GTPase Signaling, Crystallization and Solubility Studies, X-ray Diffraction in Crystallography, Biochemical and Molecular Research
Most-Cited Works
- → Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941(2009)271 cited
- → Total synthesis of erythromycins. 4. Total synthesis of erythronolide B(1978)154 cited
- → Total synthesis of erythromycins. 3. Stereoselective routes to intermediates corresponding to C(1) to C(9) and C(10) to C(13) fragments of erythronolide B(1978)115 cited
- → Mechanism-Based Screen for G1/S Checkpoint Activators Identifies a Selective Activator of EIF2AK3/PERK Signalling(2012)114 cited
- → Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer(2020)83 cited
- → Structure-Based Design of Orally Bioavailable 1H-Pyrrolo[3,2-c]pyridine Inhibitors of Mitotic Kinase Monopolar Spindle 1 (MPS1)(2013)79 cited